Literature DB >> 26266230

Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report.

Hirofumi Tomioka1, Ayano Kaneoya2, Yumi Mochizuki2, Hiroyuki Harada2.   

Abstract

Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder that is characterized by progressive cerebellar ataxia, telangiectasia, immunodeficiency, and a predisposition to leukemia/lymphoma. Here we report a rare case of lymphoma of the tongue accompanied by AT. Tumour extirpation was performed and diffuse large B-cell lymphoma was diagnosed following pathologic examination. A whole-body survey showed no other enlarged lymph nodes or tumour. The female patient then received a modified dosage of COPAD (cyclophosphamide, vinblastine, pirarubicin, and prednisolone) plus rituximab to avoid severe complications. As of follow-up after 3 years and 5 months, she remains in complete remission. Patients showing AT need careful surveillance and long-term continuous follow-up.

Entities:  

Keywords:  COPAD; Paediatrics; Tongue

Year:  2015        PMID: 26266230      PMCID: PMC4525621          DOI: 10.7860/JCDR/2015/12121.6107

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

Review 1.  Malignant lymphoma of the head and neck.

Authors:  E Zapater; J V Bagán; F Carbonell; J Basterra
Journal:  Oral Dis       Date:  2010-03       Impact factor: 3.511

2.  A review of non-Hodgkin's lymphoma of the oral cavity 1950-1980.

Authors:  Z Haidar
Journal:  J Oral Med       Date:  1986 Jul-Sep

3.  Second malignancy after treatment of childhood non-Hodgkin lymphoma.

Authors:  W Leung; J T Sandlund; M M Hudson; Y Zhou; M L Hancock; Y Zhu; R C Ribeiro; J E Rubnitz; L E Kun; B Razzouk; W E Evans; C H Pui
Journal:  Cancer       Date:  2001-10-01       Impact factor: 6.860

Review 4.  ATM: from gene to function.

Authors:  G Rotman; Y Shiloh
Journal:  Hum Mol Genet       Date:  1998       Impact factor: 6.150

5.  Cancers in 44 families with ataxia-telangiectasia.

Authors:  D Morrell; C L Chase; M Swift
Journal:  Cancer Genet Cytogenet       Date:  1990-11-01

6.  Treatment of lymphoid malignancies in patients with ataxia-telangiectasia.

Authors:  C Sandoval; M Swift
Journal:  Med Pediatr Oncol       Date:  1998-12

Review 7.  Leukemia and lymphoma in ataxia telangiectasia.

Authors:  A M Taylor; J A Metcalfe; J Thick; Y F Mak
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

8.  Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.

Authors:  Mary Gerrard; Mitchell S Cairo; Claire Weston; Anne Auperin; Ross Pinkerton; Anne Lambilliote; Richard Sposto; Keith McCarthy; Marie-José T Lacombe; Sherrie L Perkins; Catherine Patte
Journal:  Br J Haematol       Date:  2008-03-26       Impact factor: 6.998

9.  Osteosarcoma as a second tumor after treatment for primary non-Hodgkin's lymphoma in a child with ataxia-telangiectasia: presentation of a case and review of possible pathogenetic mechanisms.

Authors:  Alexandros Makis; Sophia Polychronopoulou; Stavros Haidas
Journal:  J Pediatr Hematol Oncol       Date:  2004-07       Impact factor: 1.289

  9 in total
  3 in total

1.  Childhood colon cancer in a patient with ataxia telangiectasia.

Authors:  Kyeong Min Jo; Sung Yeun Yang; Jong Ha Park; Tae Oh Kim; Heui Jeong Jeong; Chang Min Heo; Ji Hoon Jang; So Chong Hur; Na Ri Jeong; Su Jin Jeong; Sang Hoon Seol; Kyung Han Nam
Journal:  Ann Transl Med       Date:  2016-01

2.  Spontaneous Regression of Diffuse Large B-cell Lymphoma in a Patient with Ataxia-Telangiectasia.

Authors:  Roya Sherkat; Noushin Afshar Moghaddam; Nahid Reisi; Marzieh Rezaei
Journal:  Adv Biomed Res       Date:  2022-04-29

3.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.